Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 13,075 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Conditions: Cerebral Hemorrhage
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Little Rock, Arkansas • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Arthritis, Rheumatoid
Interventions: tofacitinib, adalimumab, etanercept; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 4,372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 142
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more

Conditions: Coronary Artery Disease
Interventions: PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 65
States / cities: Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more

Conditions: Acute Heart Failure
Interventions: Furosemide; Drug
Lead sponsor: Adrian Hernandez; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Post-menopause
Interventions: Study Procedures; Other
Lead sponsor: Emory University; Other
Eligibility: 45 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Graft vs Host Disease, Kidney Transplantation
Interventions: Sirolimus (RAPAMUNE); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 10 more

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 73
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more

Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions: Impella CP® placement prior to reperfusion with Primary PCI; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 46
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 41 more

Conditions: Vulvovaginitis, Vaginitis
Interventions: clindamycin phosphate/butoconazole nitrate, clindamycin phosphate, butoconazole nitrate; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 81
States / cities: Birmingham, Alabama • Enterprise, Alabama • Chandler, Arizona + 69 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions: MyoCell™ Autologous Myoblasts; Drug
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Multiple Myeloma
Interventions: Eftozanermin alfa, Bortezomib, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more

Conditions: Bladder Cancer
Interventions: cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 13
States / cities: Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Leukemia
Interventions: tipifarnib; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 56
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-02341066; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 140
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Gedeon Richter Plc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Culver City, California • Atlanta, Georgia • Bloomfield Hills, Michigan + 5 more

Conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Interventions: Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 125
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more

Conditions: Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions: Pitolisant; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 71
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more

Conditions: Constipation
Interventions: polyethyleneglycol3350; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: Started 2003
U.S. locations: 45
States / cities: Hoover, Alabama • Mobile, Alabama • Pell City, Alabama + 38 more

Conditions: Stargardt Disease
Interventions: Emixustat, Placebo; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Pemphigus
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more

Conditions: HIV-1 Infection
Interventions: Bictegravir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: Berkeley, California • Davis, California • Long Beach, California + 13 more

Search by objective public record fields.

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

SELUTION 4 De Novo Small Vessel IDE Trial

Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot

Mental Stress Reactivity in Women With CMD

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

Vaginal Infection Study

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Tipifarnib in Treating Young Patients With Refractory Leukemia

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients

Safety and Efficacy of Emixustat in Stargardt Disease

A Study of PRN1008 in Patients With Pemphigus

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants